General Partner Inc’s DexCom DXCM Stock Holding History

General Partner Inc’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-380	Closed	-$43K	–	164
2022 Q4	$43K	Buy	+380	New	+$41.7K	0.04%	152

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

General Partner Inc's DXCM Position: Q1 2023 in Review

General Partner Inc sold out of DexCom (DXCM) in Q1 2023, closing a stake of 380 shares — an estimated $43K sold.

General Partner Inc first reported a position in DXCM in Q4 2022 and held it in 1 quarter. The position peaked at $43K in Q4 2022. 904 funds tracked by Wall St. Rank hold DXCM as of Q1 2023.

General Partner Inc reported no remaining DexCom position as of Q1 2023 after selling out during the quarter.
General Partner Inc sold 380 DexCom shares in Q1 2023, an estimated $43K.
General Partner Inc first reported a position in DexCom in Q4 2022 and held it in 1 quarter.
General Partner Inc's DexCom position peaked at $43K in Q4 2022.
904 funds tracked by Wall St. Rank held DexCom as of Q1 2023.

Based on General Partner Inc's 13F filing for Q1 2023, filed 7 Apr 2023.